Look back at pharma news in week to January 11

By Barbara Obstoj-Cardwell. Editor

There was further clear evidence of major M&A activity in the start of the New Year, with Eli Lilly announcing it has agreed an $8 billion deal to acquire Loxo Oncology, following swiftly on the previous week’s $74 billion deal from Bristol-Myers to buy biotech Celgene. On the research front, Axsome impressed with mid-stage results for its major depressive disorder drug AXS-05. And among deal-making, Gilead Sciences entered into another NASH collaboration, this one with South Korea’s Yuhan Corp.

Lilly to acquire Loxo sparking targeted oncology M&A resurgence